地舒单抗与 RANKL 受体抑制剂疗效比较：更佳选择

However, whether in the comparison of individual drugs or in the classification of drugs based on mechanisms, denosumab and its represented RANKL receptor inhibitors have better therapeutic effects. 地舒单抗和其他 RANKL 受体抑制剂在治疗骨质疏松症方面具有不同的疗效。无论是单药比较还是根据机制分类的比较，地舒单抗及其代表的 RANKL 受体抑制剂都展现出更优越的疗效。这表明地舒单抗及其代表的 RANKL 受体抑制剂可能是治疗骨质疏松症的更佳选择。